Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Stanford University |
---|---|
Information provided by: | Stanford University |
ClinicalTrials.gov Identifier: | NCT00186238 |
To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Procedure: high dose chemotherapy then autologous hematopoietic cell transplant |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma |
Estimated Enrollment: | 300 |
Study Start Date: | September 1994 |
To assess the toxicity and efficacy of sequentially administered high dose cyclophosphamide and VP-16 followed by total body irradiation or BCNU and high dose mephalan and autologous stem cell rescue in the treatment of multiple myeloma.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:- received cytoreduction prior to transplant
United States, California | |
Stanford University School of Medicine | |
Stanford, California, United States, 94305 |
Principal Investigator: | Sally Arai | Stanford University |
Study ID Numbers: | BMT27, 73217, BMT27, NCT00186238 |
Study First Received: | September 13, 2005 |
Last Updated: | October 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00186238 |
Health Authority: | United States: Institutional Review Board |
Immunoproliferative Disorders Hemorrhagic Disorders Multiple myeloma Hematologic Diseases Blood Protein Disorders Blood Coagulation Disorders |
Vascular Diseases Paraproteinemias Lymphoproliferative Disorders Hemostatic Disorders Neoplasms, Plasma Cell Multiple Myeloma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases Cardiovascular Diseases |